Schizophrenia study finds new biomarker, drug candidate to treat symptoms
3 hours ago
- #biomarker
- #neuroscience
- #schizophrenia
- Current schizophrenia medications treat hallucinations and delusions but not cognitive symptoms like disorganized thinking.
- A new study identifies a novel biomarker (Cacna2d1) and potential drug candidate (SEAD1) for cognitive symptoms of schizophrenia.
- SEAD1, a synthetic protein, corrected abnormal brain activity and behavioral issues in mice without side effects.
- The study suggests a biomarker-therapeutic approach could revolutionize schizophrenia treatment by targeting specific patient subgroups.
- Future research aims to develop a blood biomarker and optimize SEAD1 for clinical trials, particularly for high-risk groups like those with 16p11.2 duplication syndrome.